Tel:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@anticorps-enligne.fr

NAT1 anticorps (AA 672-830)

Cet anticorps anti-NAT1 est un anticorps Souris Monoclonal détectant NAT1 dans WB, IHC, IP et IF. Adapté pour Humain, Souris, Rat, Boeuf (Vache) et Chien. Ce Primary Antibody a été cité dans 2+ publications.
N° du produit ABIN968148

Aperçu rapide pour NAT1 anticorps (AA 672-830) (ABIN968148)

Antigène

Voir toutes NAT1 Anticorps
NAT1 (N-Acetyltransferase 1 (Arylamine N-Acetyltransferase) (NAT1))

Reactivité

Humain, Souris, Rat, Boeuf (Vache), Chien

Hôte

  • 36
  • 3
  • 1
Souris

Clonalité

  • 37
  • 3
Monoclonal

Conjugué

  • 24
  • 3
  • 3
  • 2
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
Cet anticorp NAT1 est non-conjugé

Application

  • 28
  • 16
  • 10
  • 5
  • 5
  • 4
  • 2
  • 2
  • 1
  • 1
Western Blotting (WB), Immunohistochemistry (IHC), Immunoprecipitation (IP), Immunofluorescence (IF)

Clone

35-T1
  • Épitope

    • 7
    • 5
    • 3
    • 2
    • 2
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    AA 672-830

     Réactivité croisée

    Souris, Rat (Rattus), Chien, Boeuf (Vache)

    Attributs du produit

    1. Since applications vary, each investigator should titrate the reagent to obtain optimal results.
    2. Please refer to us for technical protocols.
    3. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
    4. Source of all serum proteins is from USDA inspected abattoirs located in the United States.

    Purification

    The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography.

    Immunogène

    Human NAT1 aa. 672-830

    Isotype

    IgG1
  • Commentaires

    Related Products: ABIN968535, ABIN967389

    Restrictions

    For Research Use only
  • Format

    Liquid

    Concentration

    250 μg/mL

    Buffer

    Aqueous buffered solution containing BSA, glycerol, and ≤0.09 % sodium azide.

    Agent conservateur

    Sodium azide

    Précaution d'utilisation

    This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

    Stock

    -20 °C

    Stockage commentaire

    Store undiluted at -20° C.
  • Henis-Korenblit, Strumpf, Goldstaub, Kimchi: "A novel form of DAP5 protein accumulates in apoptotic cells as a result of caspase cleavage and internal ribosome entry site-mediated translation." dans: Molecular and cellular biology, Vol. 20, Issue 2, pp. 496-506, (2000) (PubMed).

    Yamanaka, Poksay, Arnold, Innerarity: "A novel translational repressor mRNA is edited extensively in livers containing tumors caused by the transgene expression of the apoB mRNA-editing enzyme." dans: Genes & development, Vol. 11, Issue 3, pp. 321-33, (1997) (PubMed).

  • Antigène

    NAT1 (N-Acetyltransferase 1 (Arylamine N-Acetyltransferase) (NAT1))

    Autre désignation

    NAT1

    Sujet

    EIF-4 proteins are required for recognition of mRNA and acceleration of protein translation. This group of proteins consists of the RNA helicase eIF-4A, the RNA-binding protein eIF-4B, the cap-binding protein eIF-4E, and eIF-4G (p220). NAT1 (Novel APOBEC-1 Target no. 1), also known as DAP-5 (Death Associated Protein -5), is homologous to eIF-4G. Amino acid sequence comparison of NAT1 and eIF-4 shows that NAT1 lacks an eIF-4G N-terminal region. This region mediates eIF-4G association with eIF-4E. The highest degree of homology is within the central portions of NAT1 and eIF-4G, while the lowest degree of homology occurs at the C-terminus. NAT1 more closely resembles a cleaved form of eIF-4G that is involved in cap-independent translation. It is thought that NAT1 is involved in the repression of translation via its inhibition of both cap-dependent and cap-independent translation.
    Synonyms: Novel APOBEC-1 Target no. 1, DAP-5, Death Associated Protein -5

    Poids moléculaire

    100 kDa
Vous êtes ici:
Chat with us!